Dr. Fleshner's clinical practice is in urologic oncology with research interests in prostate and bladder cancer.
Neil E Fleshner
A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
Eur Urol. 2017 May 13;:
Oncotarget. 2017 Apr 18;8(16):25928-25941
What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy?
Can Urol Assoc J. 2017 Mar-Apr;11(3-4):118-122
Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort.
Can Urol Assoc J. 2017 Jan-Feb;11(1-2):41-46
Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.
J Clin Oncol. 2017 Apr 14;:JCO2016692327
J Natl Cancer Inst. 2017 Apr 01;109(4):
World J Urol. 2017 Feb 15;:
Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer.
Transl Oncol. 2017 Feb 03;10(2):168-177
Variant Histology and Clinicopathologic Features of Prostate Cancer in Men Aged <50 Years Treated with Radical Prostatectomy.
J Urol. 2017 Jan 24;:
The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy.
Can Urol Assoc J. 2016 Nov-Dec;10(11-12):E424-E427
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Martin Barkin Chair, Division of Urology, Department of Surgery, University of Toronto
Professor, Department of Surgery, University of Toronto